Consensus Medpace Holdings, Inc.

Equities

MEDP

US58506Q1094

Real-time Estimate Cboe BZX Other stock markets 01:36:28 2024-05-09 pm EDT			5-day change	1st Jan Change
393.4 ^USD	+1.49%		+0.39%	+28.08%

May. 08	Medpace Holdings Insider Sold Shares Worth $21,129,347, According to a Recent SEC Filing	MT
May. 03	Medpace Holdings Insider Sold Shares Worth $6,553,671, According to a Recent SEC Filing	MT

Evolution of the average Target Price on Medpace Holdings, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ee9414238eff.K78FeS8rYHGUpGFh3pkFTC98-cdj8j7qWRzYWkTOxHE.X9dpQEdzGRzb3jcZ7c0xIlxO1KROrUeAYFCcGQD7gyMajWtPakAlOezoEg~95da5ba89dd97aaeeb2fd7e547b48a60

Analyst Recommendations on Medpace Holdings, Inc.

Medpace Holdings Insider Sold Shares Worth $21,129,347, According to a Recent SEC Filing	May. 08	MT
Medpace Holdings Insider Sold Shares Worth $6,553,671, According to a Recent SEC Filing	May. 03	MT
Medpace Holdings Insider Sold Shares Worth $6,782,987, According to a Recent SEC Filing	May. 01	MT
Baird Adjusts Medpace Price Target to $454 From $446, Maintains Outperform Rating	Apr. 24	MT
Jefferies Upgrades Medpace Holdings to Buy, Price Target at $450	Apr. 23	MT
Deutsche Bank Initiates Coverage on Medpace With Hold Rating, $395 Price Target	Mar. 18	MT
UBS Adjusts Medpace Price Target to $480 From $452, Maintains Buy Rating	Mar. 08	MT
UBS Upgrades Medpace to Buy From Neutral, Adjusts Price Target to $452 From $282	Feb. 15	MT
UBS Adjusts Medpace Price Target to $282 From $270, Maintains Neutral Rating	23-10-25	MT
Baird Upgrades Medpace Holdings to Outperform From Neutral, Adjusts Price Target to $289 From $270	23-10-24	MT
UBS Adjusts Medpace Price Target to $270 From $215, Maintains Neutral Rating	23-07-26	MT
Guggenheim Raises Medpace Holdings' Price Target to $273 From $252, Keeps Buy Rating	23-07-25	MT
Guggenheim Upgrades Medpace Holdings to Buy From Neutral, Price Target is $252	23-05-08	MT
UBS Lowers Price Target on Medpace to $215 From $238, Keeps Neutral Rating	23-04-10	MT
UBS Upgrades Medpace Holdings to Neutral From Sell, Adjusts Price Target to $238 From $142	22-10-27	MT
Baird Adjusts Medpace Holdings' Price Target to $217 From $200, Keeps Neutral Rating	22-10-26	MT
Baird Adjusts Price Target on Medpace Holdings to $200 From $145, Maintains Neutral Rating	22-10-25	MT
UBS Initiates Coverage on Medpace Holdings With Sell Rating, $142 Price Target	22-09-07	MT
Baird Lowers Price Target for Medpace Holdings to $137 From $151, Maintains Neutral Rating	22-06-13	MT
Guggenheim Initiates Coverage on Medpace Holdings With Neutral Rating	22-05-24	MT
MEDPACE : Truist Adjusts Price Target on Medpace Holdings to $200 From $193, Maintains Buy Rating	21-07-27	MT
MEDPACE : Credit Suisse Adjusts Medpace Holdings' Price Target to $205 from $200, Keeps Outperform Rating	21-07-20	MT
MEDPACE : Credit Suisse Raises Medpace Holdings' PT to $200 from $181 on Strong Underlying Industry Fundamentals, Keeps Outperform Rating	21-04-20	MT
MEDPACE : Credit Suisse Raises Medpace Holdings' PT to $181 from $178, Cites Greater Visibility Into Longer Term Growth Prospects; Keeps Outperform Rating	21-03-17	MT
MEDPACE : Truist Adjusts Price Target on Medpace Holdings to $180 From $135, Reiterates Buy Rating	21-02-17	MT